About Histogenics
Histogenics is a company based in Waltham (United States) founded in 2000. Histogenics has raised $115.72 million across 6 funding rounds from investors including Stryker, Gimv and Sofinnova. The company has 69 employees as of December 31, 2024. Histogenics has completed 1 acquisition, including ProChon Biotech. Histogenics operates in a competitive market with competitors including Horizon Therapeutics, Tenaya Therapeutics, Athira Pharma, Ensoma and Orca Bio, among others.
- Headquarter Waltham, United States
- Employees 69 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ocugen, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$115.72 M (USD)
in 6 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Sep 16, 2016
-
Investors
Stryker
& 7 more
-
Employee Count
69
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Histogenics
Unlock access to complete
Finance and Accounting
1 people
Leadership Team
1 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Histogenics
Histogenics has successfully raised a total of $115.72M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Histogenics
Histogenics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Stryker, Gimv and Sofinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
US venture capital investments are made across all stages.
|
Locked | Locked | Locked | |
|
US-focused private equity and venture capital investments are managed.
|
Locked | Locked | Locked |
Investor details for Histogenics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Histogenics
Histogenics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ProChon Biotech.
Investment portfolio details for Histogenics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Regenerative biology products for cartilage lesions are developed and commercialized.
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Histogenics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Histogenics
Detailed financials for Histogenics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Histogenics Comparisons
Peer comparison for Histogenics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Histogenics
Histogenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Tenaya Therapeutics, Athira Pharma, Ensoma and Orca Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed.
|
|
| Locked | Locked | Locked |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Products for regenerative and respiratory medicine are developed and distributed.
|
Detailed competitors of Histogenics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Histogenics
Complete news archive for Histogenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Histogenics
Histogenics was founded in 2000 and raised its 1st funding round 6 years after it was founded.
Histogenics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Histogenics is a funded company, having raised a total of $115.72M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Histogenics is 69.
Histogenics was founded in 2000 and is headquartered in Waltham, United States. Focus is placed on the development of restorative cell therapies within the biotechnology sector, targeting orthopedic conditions. Operations center on proprietary regenerative technologies, including the flagship product NeoCart, by which patients knee cartilage is rebuilt using their own cells. Pain associated with cartilage damage is addressed directly, with potential to halt osteoarthritis advancement.
Histogenics's top competitors include Horizon Therapeutics, Tenaya Therapeutics and Athira Pharma.
Histogenics has made 1 acquisition, including ProChon Biotech.
Histogenics has 8 investors. Key investors include Stryker, Gimv, Sofinnova, Split Rock Partners, and Altima Partners.